Antibody-based Delivery of TNF to the Tumor Neovasculature Potentiates the Therapeutic Activity of a Peptide Anticancer Vaccine.
Amino Acid Sequence
Animals
Cancer Vaccines
/ administration & dosage
Cell Line, Tumor
Combined Modality Therapy
Disease Models, Animal
Female
Histocompatibility Antigens Class I
/ chemistry
Humans
Immunoconjugates
/ administration & dosage
Mice
Neoplasms
/ pathology
Neovascularization, Pathologic
/ immunology
Peptides
/ chemistry
Position-Specific Scoring Matrices
Tumor Necrosis Factor-alpha
/ administration & dosage
Vaccines, Subunit
/ administration & dosage
Xenograft Model Antitumor Assays
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
01
06
2018
revised:
30
08
2018
accepted:
12
10
2018
pubmed:
18
10
2018
medline:
28
2
2020
entrez:
18
10
2018
Statut:
ppublish
Résumé
There is a growing interest in the use of tumor antigens for therapeutic vaccination strategies. Unfortunately, in most cases, the use of peptide vaccines in patients does not mediate shrinkage of solid tumor masses. Peptide antigens alone exhibited only a modest tumor growth inhibition. However, anticancer activity could be substantially increased by combination with F8-TNF. Analysis of T cells in tumors and in draining lymph nodes revealed a dramatic expansion of AH1-specific CD8 Because both peptide vaccination strategies and tumor-homing TNF fusion proteins are currently being studied in clinical trials, our study provides a rationale for the combination of these 2 regimens for the treatment of patients with cancer.
Identifiants
pubmed: 30327303
pii: 1078-0432.CCR-18-1728
doi: 10.1158/1078-0432.CCR-18-1728
pmc: PMC6978140
mid: EMS84785
doi:
Substances chimiques
Cancer Vaccines
0
Histocompatibility Antigens Class I
0
Immunoconjugates
0
Peptides
0
Tumor Necrosis Factor-alpha
0
Vaccines, Subunit
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
698-709Informations de copyright
©2018 American Association for Cancer Research.
Références
Cancer Immunol Res. 2015 May;3(5):547-56
pubmed: 25672398
BMC Genomics. 2014 Mar 13;15:190
pubmed: 24621249
Blood. 2003 Dec 15;102(13):4384-92
pubmed: 12933583
J Immunol. 2014 Feb 15;192(4):1343-9
pubmed: 24511094
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Cancer Immunol Immunother. 2015 Aug;64(8):999-1009
pubmed: 25971540
Cancer Immunol Immunother. 2016 Nov;65(11):1377-1393
pubmed: 27600516
Br J Cancer. 2013 Sep 3;109(5):1206-13
pubmed: 23887603
Cancer Res. 2014 Feb 15;74(4):1045-55
pubmed: 24343228
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9730-5
pubmed: 8790399
Cancer Res. 2001 Nov 1;61(21):7920-4
pubmed: 11691813
J Cancer Res Clin Oncol. 2013 Mar;139(3):447-55
pubmed: 23160853
Cancer Res. 2002 Oct 1;62(19):5510-6
pubmed: 12359761
Nat Med. 2016 Dec;22(12):1402-1410
pubmed: 27775706
J Clin Invest. 2015 Sep;125(9):3401-12
pubmed: 26214521
Nucleic Acids Res. 2017 Jul 3;45(W1):W458-W463
pubmed: 28407089
Cancer Res. 2003 Jun 15;63(12):3202-10
pubmed: 12810649
Nat Biotechnol. 2000 Nov;18(11):1185-90
pubmed: 11062439
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
Nat Med. 2016 Apr;22(4):433-8
pubmed: 26901407
Nat Rev Clin Oncol. 2014 Sep;11(9):509-24
pubmed: 25001465
Nat Rev Immunol. 2016 Apr;16(4):207-19
pubmed: 27026073
Science. 2015 May 15;348(6236):803-8
pubmed: 25837513
Eur J Immunol. 2001 Jun;31(6):1780-9
pubmed: 11385623
Int J Cancer. 2010 Jul 1;127(1):101-10
pubmed: 19877124
Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4652-7
pubmed: 20133772
Immunity. 2000 Oct;13(4):529-38
pubmed: 11070171
J Invest Dermatol. 2013 Mar;133(3):751-758
pubmed: 23096716
Oncoimmunology. 2013 Nov 1;2(11):e26889
pubmed: 24482753
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
J Immunol. 2017 Feb 1;198(3):1357-1364
pubmed: 28011936
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Adv Cancer Res. 2013;119:421-75
pubmed: 23870514
Sci Transl Med. 2013 Sep 4;5(201):201ra118
pubmed: 24005158
Cancer Res. 2000 Feb 1;60(3):722-7
pubmed: 10676659
J Immunol. 2010 Nov 1;185(9):5048-55
pubmed: 20921533
Blood. 2008 Oct 1;112(7):2628-35
pubmed: 18574027
Int J Cancer. 2008 Jun 1;122(11):2405-13
pubmed: 18271006
Eur J Immunol. 2016 Feb;46(2):319-28
pubmed: 26495903
J Virol. 1982 Jul;43(1):26-36
pubmed: 6287001
Nat Commun. 2018 Mar 15;9(1):1092
pubmed: 29545564
Nat Rev Cancer. 2005 Jun;5(6):436-46
pubmed: 15928674
J Surg Oncol. 2013 Feb;107(2):173-9
pubmed: 22674435
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249
pubmed: 27799536
Cancer Res. 2017 Jul 1;77(13):3644-3654
pubmed: 28484076
Cancer Res. 2007 Nov 15;67(22):10948-57
pubmed: 18006840
Leuk Res. 2009 Dec;33(12):1718-22
pubmed: 19625084